Newfoundland and Labrador-based biotechnology company Sequence Bio has been selected to present at BIO Digital 2021, a premier biotech event that brings together biotech leaders from around the world through global partnerships, collaboration, and thought leadership.
The presentation by Dr. Richard A. Leach, Chief Strategy Officer, will detail how Sequence Bio is tackling the urgent, global need for improved drug target discovery, including an overview of the company’s Target Discovery Platform which combines variant-enriched genetics, other omics, and deep health information for more efficient and effective discovery of novel drug targets.
This presentation will be available to registered attendees on Thursday, June 10 at 7:30 am NT.
BIO Digital is scheduled to run June 10-11 & 14-18, 2021. Attendees will be able to view Sequence Bio’s company presentation before live meetings in the BIO One-on-One Partnering™ system begin on Monday, June 14.
Sequence Bio is a Newfoundland and Labrador-based biotechnology company accelerating novel target identification with custom discovery and validation cohorts.
By combining founder population multi-omics with medical and other health information, Sequence Bio’s target discovery platform is purpose-built to produce bespoke cohorts, supported by custom phenotyping, for more efficient and effective discovery and validation of novel drug targets.
BIO is the world's largest advocacy organization representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.
VP, Market Development